TITLE

Two New Drugs Approved for Treatment of Hepatitis C

PUB. DATE
June 2011
SOURCE
Internal Medicine Alert;6/15/2011 Supplement, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers updates related to pharmacology in the U.S. which include the new drugs approved by the Food & Drug Administration (FDA) for the treatment of hepatitis C, the risks of nonsteroidal anti-inflammatory drug (NSAID), and FDA's approval of linagliptin for treatment of type 2 diabetes.
ACCESSION #
63988794

 

Related Articles

  • Generic Drug Salsalate Continues to Show Promise. Alexander, Michael // Diabetes Health;Jun/Jul2010, Vol. 19 Issue 3, p41 

    The article reports that a three-month trial of salsalate, a generic aspirin-like drug, significantly improved blood glucose levels. Patients taking salsalate experienced a 0.5% decline in their hemoglobin A1c levels. Investigations into the potential of salsalate as a drug for type 2 diabetes...

  • First Anti-Inflammatory Generic Drug Promising New Therapy for Diabetes. Buffery, Dalia // American Health & Drug Benefits;Mar2010, Vol. 3 Issue 2, p106 

    The article discusses research into a generic drug, salsalate, which could potentially treat both arthritis and type 2 diabetes. The study results could have major implications for the use of generic medications in the U.S. due to the potential cost-savings. The author notes that the drug...

  • The Impact of Salsalate Treatment on Serum Levels of Advanced Glycation End Products in Type 2 Diabetes. Barzilay, Joshua I.; Jablonski, Kathleen A.; Fonseca, Vivian; Shoelson, Steven E.; Goldfine, Allison B.; Strauch, Christopher; Monnier, Vincent M. // Diabetes Care;Apr2014, Vol. 37 Issue 4, p1083 

    Salsalate is a nonacetylated salicylate that lowers glucose levels in people with type 2 diabetes (T2D). Here we examined whether salsalate also lowered serum-protein-bound levels of early and advanced glycation end products (AGEs) that have been implicated in diabetic vascular complications....

  • Two new diabetes drugs on the market.  // Cardiology Today;Mar2012, Vol. 15 Issue 3, p35 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of two drugs indicated for the treatment of type 2 diabetes.

  • Colesevelam: A novel drug for comorbid diabetes and dyslipidemia. Dixit, Alok; Pandey, Pinki // Chronicles of Young Scientists;Oct-Dec2012, Vol. 3 Issue 4, p312 

    The article discusses the approval of the colesevelam hydrochloride by the U.S. Food and Drug Administration for type 2 diabetes mellitus and dyslipidemia. It mentions that the drug is approved as adjunctive treatment for T2DM in combination with sulfonylurea, metformin, and insulin therapy. It...

  • New Amylin Diabetes Drug Beats Its Current Offering. Chambers, Heather // San Diego Business Journal;12/21/2009, Vol. 30 Issue 51, p13 

    The article reports on claims of San Diego, California-based biotechnology company Amylin Pharmaceuticals Inc. that its once-weekly experimental type two diabetes drug, Byetta, surpassed its twice-daily drug in a trial. This trial involved 250 participants with type two diabetes who were...

  • FDA APPROVAL MARKS NEW DRUG CLASS FOR TYPE 2 DIABETES.  // Medical Economics;4/10/2013, Vol. 90 Issue 7, p71 

    The article offers information about the drug Canaglifozin tablet from Janssen Pharmaceuticals Inc. which has been approved by the U.S. Food and Drug Administration (FDA) for the improvement of glycemic control in adult with type 2 diabetes.

  • Untitled. Cornell, Susan // Pharmacy Today;May2013 Product Bulletin, p2 

    An introduction is presented in which the author discusses canagliflozin (INVOKANA â„¢) from Janssen Pharmaceuticals Inc. approved by the U.S. Food and Drug Administration (FDA) in March 2013 which is considered as the first in anew drug class for treating type 2 diabetes.

  • FDA actions.  // Neurology Alert;Jul2011 Pharmacology Watch, p2 

    The article reports on the actions taken by the U.S. Food and Drug Administration on several drugs including the approval of linagliptin for type 2 diabetes in adults and rilpivirine for adults with HIV-1 and the eventual pulling out of Rosiglitazone (Avandia) from the U.S. market.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics